Pressreleases

Promega Introduces Bioluminescent HDAC Assays that are up to 100-fold More Sensitive than Comparable Fluorescence-Based Assays

Promega Corporation announced today the launch of highly sensitive bioluminescent assays for the measurement of the relative activities of histone deacetylases (HDAC) for basic research, screening and drug discovery. The new HDAC-Glo™ and SIRT-Glo™ Assays and Screening Systems use a single-reagent-addition, add-mix-measure protocol for easy implementation in bench top to high throughput screening applications, reducing labor and time to results.

Promega Introduces Four New Proteases

Promega Corporation announced today that it has launched four new proteases, Pepsin, Elastase, Sequencing Grade Arg-C, and Thermolysin. These high quality proteases are the latest addition to Promega's market leading range of protein sample prep reagents, which includes Trypsin Gold.

Promega Introduces Kits Enabling High Yield Purification of gDNA from Challenging Blood and Tissue Samples

Promega Corporation announced today that it has launched the ReliaPrep™ Blood and Tissue gDNA Miniprep Systems, for the extraction of high yields of very pure gDNA from even the most challenging samples, such as frozen blood. The new kits have been designed to use with small sample volumes and purify clean gDNA without ethanol, which can inhibit downstream applications.

Promega Introduces Mitochondrial ToxGlo Assay for Identification of Mitochondrial…

Promega Corporation announced today the launch of the Mitochondrial ToxGlo™ Assay, a cell-based assay that enables researchers to quickly profile large compound libraries or medicinal modifications for their effects on mitochondria by allowing them to distinguish primary mitochondrial dysfunction from secondary cytotoxic events in a single well via a sequential-addition, multiplexed assay chemistry.

Promega Introduces ONE-Glo + Tox Luciferase Reporter and Cell Viability Assays for Improved Reporter Gene Expression Analysis

Promega Corporation announced today the launch of ONE-Glo™ + Tox Assay, for improved analysis of reporter gene expression in the context of cell health. The assay combines luciferase chemistry with a cell viability marker in a two-step, addition-only process, to enable measurement of cell viability and gene expression in a single well of a plate, negating the need to run parallel assays. By analyzing reporter activity in relation to cell viability, false results due to toxicity or changes in cell number can be uncovered.

Promega Partners with ATCC to Offer New Cell Systems for Biologics Drug Discovery

Promega Corporation and ATCC (historically known as the American Type Culture Collection) have formed a partnership for the cell banking and bioproduction of cells to create a new line of bioluminescence-based drug discovery assays for biologics.

Promega Protocols & Applications App Now Available for Android Devices

The Promega App, containing protocols, reference information and molecular biology calculators, is now available for Android. With this release, the popular Promega App is now available on both Apple and Android devices

Promega Surpasses Environmental Goals in 2010

Promega Corporation made significant progress in meeting and exceeding its 2012 environmental impact goals. The recently published Promega 2010 Corporate Responsibility Report, details all six 2012 goals and the achievement of reaching four of them by 2010.

Promega to Offer Leading Transfection Tool FuGENE® 6

Promega Corporation and Fugent LLC recently signed a supply agreement that establishes Promega as a provider of the leading transfection tool FuGENE® 6. This agreement ensures that researchers will continue to have access to the FuGENE® transfection reagents they have always used in their daily research. This expands on the existing Promega/Fugent agreement for supply of the FuGENE® HD Transfection reagent.